GlassScriptPhysician profile
Rani Kumaran
NPI 1467616144
$3,047.33
in general payments reported to CMS, 2019-2025
23 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $345 · 2021: $228 · 2022: $298 · 2023: $266 · 2024: $292 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $673.47 | 2019 | |
| Glaxosmithkline, LLC. | $540.92 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.38 | 2019-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $246.78 | 2021-2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $192.37 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Inspire Medical Systems, INC. | $179.20 | 2020-2025 | Inspire |
| Philips North America LLC | $132.69 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $87.74 | 2025 | Dupixent |
| Mylan Specialty L.P. | $84.58 | 2022-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $79.56 | 2023-2025 | Opsumit, Uptravi |
| Baxter Healthcare | $68.98 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $63.26 | 2024-2025 | |
| Grifols USA, LLC | $60.73 | 2024-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $53.62 | 2022-2023 | Airduo Digihaler |
| Viatris Specialty LLC | $53.26 | 2025 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.48 | 2024-2025 | Glassia |
| Insmed, INC. | $30.57 | 2025 | Arikayce |
| Harmony Biosciences LLC | $29.17 | 2025 | |
| Verona Pharma, INC. | $23.22 | 2025 | Ohtuvayre |
| Pfizer INC. | $19.71 | 2022 | |
| Resmed Corp | $18.37 | 2022 | |
| Gilead Sciences, INC. | $15.65 | 2022 | |
| Advanced Respiratory, INC | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Kumaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.